Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
World Community Grid
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===FightAIDS@Home=== {{Main|FightAIDS@Home}} '''FightAIDS@Home''' (launched November 19, 2005<ref name="FightAIDSatHome-PR" />) was World Community Grid's second project and its first to target a single disease. Each individual computer processes one potential drug molecule and tests how well it would [[docking (molecular)|dock]] with [[HIV]] [[protease]], acting as a [[Protease inhibitor (pharmacology)|protease inhibitor]].<ref name="FightAIDSatHome-WCG" /> Scripps Research Institute published its first peer-reviewed scientific paper about the results of FightAIDS@Home on April 21, 2007.<ref>{{cite journal | vauthors = Chang MW, Lindstrom W, Olson AJ, Belew RK | title = Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries | journal = Journal of Chemical Information and Modeling | volume = 47 | issue = 3 | pages = 1258β62 | date = 2007-04-21 | pmid = 17447753 | doi = 10.1021/ci700044s | publisher = [[American Chemical Society]] | doi-access =free }}</ref> This paper explains that the results up to that point will primarily be used to improve the efficiency of future FightAIDS@Home calculations.<ref>{{cite web |url=http://fightaidsathome.scripps.edu/news/vol3.pdf |title=FightAIDS@Home News Volume 3 |publisher=[[The Scripps Research Institute]] |date=2007-05-10 |access-date=2007-07-30 |archive-date=2007-08-08 |archive-url=https://web.archive.org/web/20070808120748/http://fightaidsathome.scripps.edu/news/vol3.pdf |url-status=live }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)